688319 Stock Overview
Engages in the research and development, production, and sale of human vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688319 from our risk checks.
Chengdu Olymvax Biopharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.73 |
| 52 Week High | CN¥20.40 |
| 52 Week Low | CN¥7.06 |
| Beta | 0.61 |
| 11 Month Change | 5.20% |
| 3 Month Change | 34.98% |
| 1 Year Change | -40.70% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688319 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 10.5% | -1.9% | -2.8% |
| 1Y | -40.7% | -21.0% | 2.0% |
Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -21% over the past year.
Return vs Market: 688319 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 688319 volatility | |
|---|---|
| 688319 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688319 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688319's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 468 | Shaowen Fan | www.olymvax.com |
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and Staphylococcus aureus, which is in Phase 3 clinical trial.
Chengdu Olymvax Biopharmaceuticals Inc. Fundamentals Summary
| 688319 fundamental statistics | |
|---|---|
| Market cap | CN¥4.76b |
| Earnings (TTM) | -CN¥8.70m |
| Revenue (TTM) | CN¥530.47m |
9.0x
P/S Ratio-547.2x
P/E RatioIs 688319 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688319 income statement (TTM) | |
|---|---|
| Revenue | CN¥530.47m |
| Cost of Revenue | CN¥32.08m |
| Gross Profit | CN¥498.39m |
| Other Expenses | CN¥507.09m |
| Earnings | -CN¥8.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 93.95% |
| Net Profit Margin | -1.64% |
| Debt/Equity Ratio | 41.0% |
How did 688319 perform over the long term?
See historical performance and comparison